Psychemedics Corp Relocates HQ to Dallas, TX
Ticker: PMDI · Form: 8-K · Filed: Jan 26, 2024 · CIK: 806517
| Field | Detail |
|---|---|
| Company | Psychemedics Corp (PMDI) |
| Form Type | 8-K |
| Filed Date | Jan 26, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.005, $190,000, $285,000 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, relocation
TL;DR
**PMD moved its HQ from Massachusetts to Dallas, TX on Jan 22, 2024.**
AI Summary
Psychemedics Corporation (PMD) announced on January 22, 2024, that it has changed its principal executive offices from Acton, Massachusetts, to 5220 Spring Valley Road, Suite 230, Dallas, TX 75254. This move signifies a relocation of their main operations. For investors, this matters because a change in headquarters can sometimes indicate a strategic shift, a desire to be closer to a new talent pool, or a move to a more business-friendly environment, potentially impacting future operational costs and efficiency.
Why It Matters
This relocation could signal a strategic shift for Psychemedics, potentially impacting operational costs, access to talent, and overall business strategy, which could influence future financial performance.
Risk Assessment
Risk Level: low — A change in corporate address is generally a low-risk event, as it doesn't directly impact the company's core business or financial health in the short term.
Analyst Insight
Investors should monitor future filings for any strategic announcements or financial impacts related to the relocation, such as changes in operating expenses or new business initiatives, to understand the long-term implications of this move.
Key Players & Entities
- PSYCHEMEDICS CORPORATION (company) — the registrant
- Acton, Massachusetts (location) — former principal executive offices
- 5220 Spring Valley Road, Suite 230, Dallas, TX 75254 (location) — new principal executive offices
- January 22, 2024 (date) — date of earliest event reported
- PMD (company) — trading symbol
Forward-Looking Statements
- Psychemedics Corporation will experience a slight increase in operational efficiency due to the relocation. (PSYCHEMEDICS CORPORATION) — low confidence, target: 2025-01-22
FAQ
What was the previous address of Psychemedics Corporation's principal executive offices?
The previous address for Psychemedics Corporation's principal executive offices was 289 Great Road, Acton, Massachusetts 01720.
What is the new address for Psychemedics Corporation's principal executive offices?
The new address for Psychemedics Corporation's principal executive offices is 5220 Spring Valley Road, Suite 230, Dallas, TX 75254.
When did the change in principal executive offices for Psychemedics Corporation take effect?
The earliest event reported, which includes the change in principal executive offices, occurred on January 22, 2024.
What is the trading symbol for Psychemedics Corporation's common stock?
The trading symbol for Psychemedics Corporation's common stock is PMD.
On which exchange is Psychemedics Corporation's common stock registered?
Psychemedics Corporation's common stock is registered on The NASDAQ Stock Market, LLC.
Filing Stats: 683 words · 3 min read · ~2 pages · Grade level 13.9 · Accepted 2024-01-26 16:10:21
Key Financial Figures
- $0.005 — nge on which registered Common stock. $0.005 par value PMD The NASDAQ Stock Market
- $190,000 — ed bonus established under this plan is $190,000, with a maximum amount of $285,000. The
- $285,000 — n is $190,000, with a maximum amount of $285,000. The actual bonus award, if any, will b
Filing Documents
- f8k_012624.htm (8-K) — 23KB
- 0001171843-24-000431.txt ( ) — 232KB
- pmd-20240122.xsd (EX-101.SCH) — 3KB
- pmd-20240122_def.xml (EX-101.DEF) — 26KB
- pmd-20240122_lab.xml (EX-101.LAB) — 35KB
- pmd-20240122_pre.xml (EX-101.PRE) — 24KB
- f8k_012624_htm.xml (XML) — 4KB
02
ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS (e) On January 22, 2024, the Compensation Committee of the Board of Directors of the Corporation approved the terms of cash performance bonus arrangements. 2024 Chief Executive Officer's Performance Bonus Plan At the January 22, 2024 meeting, the Compensation Committee approved a 2024 cash bonus plan for Brian Hullinger, the Corporation's Chief Executive Officer, that includes corporate financial performance targets and individual performance goals. The overall targeted bonus established under this plan is $190,000, with a maximum amount of $285,000. The actual bonus award, if any, will be determined based upon the level of achievement of the established performance targets and goals as determined by the Compensation Committee. 2024 Other Executive Officer Cash Bonus Plan Also at its January, 22, 2024 meeting, the Compensation Committee approved a 2024 cash bonus plan for other executive officers corporate that includes financial performance targets and individual performance goals. The target amounts of such cash bonuses range from 25% to 40% of base salary for each of the officers. The actual amount of each cash bonus, if any, will be subject to increase or decrease at the discretion of the Compensation Committee. Following the end of fiscal year 2024, the Chief Executive Officer will review and assess the performance of each of the other participants with respect to achievement of his or her individual goals and provide his recommendations thereon to the Compensation Committee. In addition, the Compensation Committee will review and assess the Chief Executive Officer's performance with respect to achievement of his individual goals. The Compensation Committee will then determine the level of payout of the portion of the Chief Executive Officer's bonus arrangement with respect to individual and compan